Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Grechko N, Skarbova V, Tomaszewska-Kiecana M, Ramlau R, Centkowski P, Drew Y, Dziadziuszko R, Zemanova M, Beltman J, Nash E, Habeck J, Liao M, Xiao J. Grechko N, et al. Among authors: nash e. Cancer Chemother Pharmacol. 2021 Aug;88(2):259-270. doi: 10.1007/s00280-021-04278-2. Epub 2021 Apr 28. Cancer Chemother Pharmacol. 2021. PMID: 33909097 Free PMC article. Clinical Trial.
Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
Xiao JJ, Nowak D, Ramlau R, Tomaszewska-Kiecana M, Wysocki PJ, Isaacson J, Beltman J, Nash E, Kaczanowski R, Arold G, Watkins S. Xiao JJ, et al. Among authors: nash e. Clin Transl Sci. 2019 Jan;12(1):58-65. doi: 10.1111/cts.12600. Epub 2018 Dec 20. Clin Transl Sci. 2019. PMID: 30427584 Free PMC article. Clinical Trial.
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors.
Liao M, Watkins S, Nash E, Isaacson J, Etter J, Beltman J, Fan R, Shen L, Mutlib A, Kemeny V, Pápai Z, van Tilburg P, Xiao JJ. Liao M, et al. Among authors: nash e. Invest New Drugs. 2020 Jun;38(3):765-775. doi: 10.1007/s10637-019-00815-2. Epub 2019 Jun 27. Invest New Drugs. 2020. PMID: 31250355 Free PMC article. Clinical Trial.
A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Liao M, Jeziorski KG, Tomaszewska-Kiecana M, Láng I, Jasiówka M, Skarbová V, Centkowski P, Ramlau R, Górnaś M, Lee J, Edwards S, Habeck J, Nash E, Grechko N, Xiao JJ. Liao M, et al. Among authors: nash e. Cancer Chemother Pharmacol. 2021 Nov;88(5):887-897. doi: 10.1007/s00280-021-04338-7. Epub 2021 Aug 9. Cancer Chemother Pharmacol. 2021. PMID: 34370076 Free PMC article. Clinical Trial.
Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia.
Nash E, Nicoll A, Batt N, George J, Perananthan V, Prince D, Wallace M, Gow P, Vaz K, Chitturi S, Flores JE, Braund A, Bonnichsen M, Riordan S, Humphris J, Duong T, McKenzie C, Liu K, Strasser SI. Nash E, et al. Aliment Pharmacol Ther. 2024 Apr;59(8):953-961. doi: 10.1111/apt.17906. Epub 2024 Feb 19. Aliment Pharmacol Ther. 2024. PMID: 38372012
Reductions in spice lead levels in the republic of Georgia: 2020-2022.
Forsyth JE, Akhalaia K, Jintcharadze M, Nash E, Sharov P, Temnikova A, Elmera C. Forsyth JE, et al. Among authors: nash e. Environ Res. 2024 Jun 1;250:118504. doi: 10.1016/j.envres.2024.118504. Epub 2024 Feb 15. Environ Res. 2024. PMID: 38367836
277 results